NFKB1 and lymphoma: Despite the fact that our cohort is relatively small, we found oncologic manifestations in 29% of our cases (two thirds being lymphoma), suggesting that malignancies in patients with NFKB1 haploinsufficiency can occur more often than in unselected patients with CVID.